EUR 4.6
(-3.97%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 1.5 Million EUR | -56.11% |
2022 | 28.97 Million EUR | 74.19% |
2021 | 16.63 Million EUR | 273.04% |
2020 | 4.45 Million EUR | 33109.04% |
2019 | 13.42 Thousand EUR | 1533.7% |
2018 | 822.00 EUR | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 FY | 12.71 Million EUR | -56.11% |
2023 Q2 | - EUR | 0.0% |
2022 Q2 | 1.15 Million EUR | 0.0% |
2022 Q4 | - EUR | -100.0% |
2022 FY | 28.97 Million EUR | 74.19% |
2021 FY | 16.63 Million EUR | 273.04% |
2021 Q2 | 434.15 Thousand EUR | -92.95% |
2020 Q2 | 147.45 Thousand EUR | 0.0% |
2020 FY | 4.45 Million EUR | 33109.04% |
2020 Q4 | 6.15 Million EUR | 4075.59% |
2019 FY | 13.42 Thousand EUR | 1533.7% |
2018 FY | 822.00 EUR | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
MPH Health Care AG | 4.22 Million EUR | 64.316% |
Apontis Pharma AG | 23.17 Million EUR | 93.499% |
Dermapharm Holding SE | 142.51 Million EUR | 98.943% |
Evotec SE | 222.55 Million EUR | 99.323% |
MERCK Kommanditgesellschaft auf Aktien | 8.82 Billion EUR | 99.983% |
PharmaSGP Holding SE | 50.72 Million EUR | 97.03% |